Psychiatry Internship Program, University of Bourgogne, 21000, Dijon, France.
Department of Internal Medicine and sub-Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon.
Lipids Health Dis. 2020 Feb 7;19(1):22. doi: 10.1186/s12944-020-01203-z.
Antipsychotic-induced weight gain is the most prevalent somatic adverse event occurring in patients treated by antipsychotics, especially atypical antipsychotics. It is of particular interest because of its repercussion on cardiovascular morbidity and mortality especially now that the use of second-generation antipsychotics has been extended to other mental health illnesses such as bipolar disorders and major depressive disorder. The mechanism underlying antipsychotics-induced weight gain is still poorly understood despite a significant amount of work on the topic. Recently, there has been an on-going debate of tremendous research interest on the relationship between antipsychotic-induced weight gain and body weight regulatory hormones such as leptin. Given that, researchers have brought to light the question of leptin's role in antipsychotic-induced weight gain. Here we summarize and discuss the existing evidence on the link between leptin and weight gain related to antipsychotic drugs, especially atypical antipsychotics.
抗精神病药引起的体重增加是接受抗精神病药物治疗的患者中最常见的躯体不良事件，尤其是非典型抗精神病药。这是特别值得关注的，因为它对心血管发病率和死亡率有影响，尤其是现在第二代抗精神病药物已经被扩展用于治疗其他精神疾病，如双相情感障碍和重度抑郁症。尽管在这一主题上进行了大量研究，但抗精神病药引起的体重增加的机制仍未被很好地理解。最近，关于抗精神病药引起的体重增加与瘦素等体重调节激素之间的关系，人们展开了一场极具研究兴趣的争论。鉴于此，研究人员提出了瘦素在抗精神病药引起的体重增加中的作用的问题。在这里，我们总结和讨论了关于瘦素与抗精神病药物（尤其是非典型抗精神病药）相关体重增加之间的关联的现有证据。
